严建亚父女低调现身 巨子生物发力百亿“注射”市场

Core Insights - The strategic partnership between Nordberg Medical and the company aims to leverage proprietary synthetic biology technology to advance the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields [1][2] - The company is at a critical juncture as its main brand "Kefumei" faces declining online traffic and increasing price competition, despite maintaining a revenue and profit growth rate of around 20% [1][2] - A newly approved Class III medical device registration certificate marks a significant shift in the company's business logic, allowing its products to transition from skincare to professional medical applications [1][4] Financial Performance - In the first half of 2025, the company reported revenue of 3.113 billion yuan, a year-on-year increase of 22.5%, and a net profit of 1.182 billion yuan, also showing over 20% growth [2] - Sales costs increased by 27.5% year-on-year to 570 million yuan, outpacing revenue growth and putting pressure on gross margins [2][3] - R&D expenses decreased by 15.5% to 41.2 million yuan, attributed to some projects entering the results transformation phase, while tax expenses surged by 49.9%, further impacting net profit growth [3] Market Dynamics - The core brand "Kefumei" generated revenue of 2.54 billion yuan, reflecting a 22.7% year-on-year growth, but faces challenges from industry slowdowns and intensified competition [3][4] - Reports indicate a double-digit decline in sales during the Double Eleven shopping festival, with significant drops in GMV on platforms like Douyin, highlighting the need for a strategic shift from scale expansion to profit stabilization and structural adjustment [3] Strategic Shift - The newly acquired medical device registration certificate allows the company to compete in the B2B market against peers like Jinbo Biotechnology, paving the way for future compliant products [4] - The partnership with Nordberg Medical represents a strategic "borrowing a boat to go to sea" approach, enabling the company to utilize established global networks for market entry without starting from scratch [5] - The focus on professional attributes of products necessitates a restructuring of marketing and distribution strategies, targeting broader overseas markets while enhancing B2B and B2C brand recognition [5][6] Organizational Focus - The company's leadership is shifting resources towards products with global registration potential, indicating a strategic pivot from consumer-driven growth to a dual-engine model of "consumer brand" and "professional technology" [6] - The strategic path is clear: domestically, the company aims to penetrate medical aesthetics institutions with its registered products, while internationally, it seeks to enter the global regenerative aesthetics market through technology licensing and joint development [6]